Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
Ayala Pharmaceuticals (NASDAQ: AYLA) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 5:00 PM GMT (12:00 PM ET). The event will be accessible via a live webcast on Ayala's website, with an archived replay available for 90 days post-event. Ayala focuses on developing small molecule therapeutics for rare cancers, with two key candidates, AL101 and AL102, in clinical trials. AL101 has received Fast Track and Orphan Drug Designation from the FDA, targeting tumors with Notch activating mutations.
- None.
- None.
REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).
A live webcast of the fireside chat may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.
Contacts:
Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com
Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
FAQ
When is Ayala Pharmaceuticals participating in the Jefferies London Healthcare Conference?
How can I access the Ayala Pharmaceuticals fireside chat webcast?
What are the key product candidates under development by Ayala Pharmaceuticals?
What designations has AL101 received from the FDA?
What types of tumors do Ayala's therapies target?
